Predictive Oncology (AGPU) Competitors

Neuronetics has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Predictive Oncology has a beta of 3.45, meaning that its stock price is 245% more volatile than the S&P 500.

Neuronetics currently has a consensus target price of $3.00, suggesting a potential upside of 38.25%. Given Neuronetics' stronger consensus rating and higher probable upside, equities analysts clearly believe Neuronetics is more favorable than Predictive Oncology.

In the previous week, Neuronetics had 6 more articles in the media than Predictive Oncology. MarketBeat recorded 9 mentions for Neuronetics and 3 mentions for Predictive Oncology. Neuronetics' average media sentiment score of 0.39 beat Predictive Oncology's score of 0.13 indicating that Neuronetics is being referred to more favorably in the media.

Neuronetics has higher revenue and earnings than Predictive Oncology. Neuronetics is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

53.6% of Neuronetics shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 8.4% of Neuronetics shares are held by insiders. Comparatively, 1.2% of Predictive Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Neuronetics has a net margin of -26.15% compared to Predictive Oncology's net margin of -185,476.72%. Predictive Oncology's return on equity of 0.00% beat Neuronetics' return on equity.

Fonar has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Predictive Oncology has a beta of 3.45, meaning that its stock price is 245% more volatile than the S&P 500.

Fonar has higher revenue and earnings than Predictive Oncology. Predictive Oncology is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks.

In the previous week, Predictive Oncology had 3 more articles in the media than Fonar. MarketBeat recorded 3 mentions for Predictive Oncology and 0 mentions for Fonar. Fonar's average media sentiment score of 1.91 beat Predictive Oncology's score of 0.13 indicating that Fonar is being referred to more favorably in the media.

50.6% of Fonar shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 1.6% of Fonar shares are owned by company insiders. Comparatively, 1.2% of Predictive Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Fonar has a net margin of 7.13% compared to Predictive Oncology's net margin of -185,476.72%. Fonar's return on equity of 4.69% beat Predictive Oncology's return on equity.

Nyxoah has a beta of 1.56, meaning that its stock price is 56% more volatile than the S&P 500. Comparatively, Predictive Oncology has a beta of 3.45, meaning that its stock price is 245% more volatile than the S&P 500.

Nyxoah has a net margin of -884.69% compared to Predictive Oncology's net margin of -185,476.72%. Predictive Oncology's return on equity of 0.00% beat Nyxoah's return on equity.

Nyxoah has higher revenue and earnings than Predictive Oncology. Nyxoah is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

In the previous week, Predictive Oncology had 1 more articles in the media than Nyxoah. MarketBeat recorded 3 mentions for Predictive Oncology and 2 mentions for Nyxoah. Predictive Oncology's average media sentiment score of 0.13 beat Nyxoah's score of 0.00 indicating that Predictive Oncology is being referred to more favorably in the news media.

Nyxoah presently has a consensus target price of $9.33, suggesting a potential upside of 214.25%. Given Nyxoah's stronger consensus rating and higher probable upside, research analysts plainly believe Nyxoah is more favorable than Predictive Oncology.

9.0% of Predictive Oncology shares are owned by institutional investors. 1.2% of Predictive Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Treace Medical Concepts presently has a consensus target price of $4.77, suggesting a potential upside of 153.72%. Given Treace Medical Concepts' stronger consensus rating and higher possible upside, equities research analysts clearly believe Treace Medical Concepts is more favorable than Predictive Oncology.

Treace Medical Concepts has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Predictive Oncology has a beta of 3.45, indicating that its stock price is 245% more volatile than the S&P 500.

Treace Medical Concepts has a net margin of -27.74% compared to Predictive Oncology's net margin of -185,476.72%. Predictive Oncology's return on equity of 0.00% beat Treace Medical Concepts' return on equity.

Treace Medical Concepts has higher revenue and earnings than Predictive Oncology. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

In the previous week, Treace Medical Concepts had 2 more articles in the media than Predictive Oncology. MarketBeat recorded 5 mentions for Treace Medical Concepts and 3 mentions for Predictive Oncology. Treace Medical Concepts' average media sentiment score of 0.27 beat Predictive Oncology's score of 0.13 indicating that Treace Medical Concepts is being referred to more favorably in the media.

84.1% of Treace Medical Concepts shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 23.4% of Treace Medical Concepts shares are held by insiders. Comparatively, 1.2% of Predictive Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.